CASE REPORT

Long-term response with durvalumab after chemoradiotherapy for pulmonary pleomorphic carcinoma: A case report

Takafumi Yorozuya1, Tetsuya Taya1, Kento Yasuda1, Yutaro Nagano1, Makoto Shioya1, Hirofumi Chiba2 & Hiroki Takahashi2

1 Department of Respiratory Medicine, Wakamatsu, Otaru General Hospital, Otaru, Japan
2 Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, Sapporo, Japan

Keywords
Chemoradiotherapy; durvalumab; immune checkpoint inhibitor; pleomorphic carcinoma; programmed death-ligand 1.

Abstract
Pulmonary pleomorphic carcinoma (PPC) is a non-small-cell lung cancer, resistant to chemotherapy and no standard therapy has as yet been established. We herein report the case of a 59-year-old man with PPC who showed a long-term response with durvalumab after chemoradiotherapy. He was referred to our hospital with a mass shadow at the right upper lung. PPC clinical stage IIIB was diagnosed, and the tumor proportion score of programmed death-ligand 1 (PD-L1) was 100%. Six days after transbronchial biopsy, he had difficulty walking owing to sensory abnormalities. We found that the primary tumor had invaded the spinal cord and compressed the cord at T1–T4, resulting in the abnormalities. He underwent tumor resection and received chemotherapy involving cisplatin (CDDP) + S-1 and concurrent radiotherapy (66 Gy). Subsequently, durvalumab treatment as consolidation therapy was commenced. After one year of durvalumab treatment had been completed, he had no apparent signs of relapse or severe adverse events. This case suggests that a long-term response can be achieved with durvalumab after chemoradiotherapy for stage III inoperable PPC showing high PD-L1 expression.

Key Points
- Significant findings of the report: A long-term response might be achieved with durvalumab after chemoradiotherapy in patients with stage III inoperable pulmonary pleomorphic carcinoma showing high expression of programmed death-ligand 1.
- What this study adds: It is possible to continue durvalumab treatment for one year without any severe adverse events. Although pulmonary pleomorphic carcinoma is considered to have a poor prognosis, the combination therapy of immune checkpoint inhibitors and radiotherapy may be an effective treatment option.

Introduction
Pulmonary pleomorphic carcinoma (PPC) is rare and represents less than 1% of all lung cancers. A standard treatment for PPC has not been established because of its rarity. PPC is resistant to chemotherapy and has a poor prognosis. Recently, several studies have highlighted that PPC highly expresses programmed death-ligand 1 (PD-L1), and several cases of successful treatment with immune checkpoint inhibitors (ICIs) have been reported. We herein report a rare case of a patient with stage III inoperable PPC showing high PD-L1 expression, who experienced a long-term response with durvalumab after chemoradiotherapy.
Case report

A 59-year-old man experienced pain in his right back for two months previously. He was subsequently referred to our hospital with a mass shadow visible on chest x-ray of the his right upper lung (Fig 1). He had a history of paroxysmal supraventricular tachycardia, and was an ex-smoker with a Brinkman index of 800. Transbronchial biopsy (TBB) was performed, and he was diagnosed with PPC in August 2018 (Fig 2). Epidermal growth factor receptor (EGFR) gene mutations and the anaplastic lymphoma kinase gene were not detected. The tumor proportion score (TPS) of PD-L1 was 100%. Six days after TBB, he experienced difficulty walking because of sensory abnormalities on the inside of the upper arm and from the abdomen to the lower legs. We found that the primary tumor had invaded around the spinal cord and compressed the cord at T1–T4, resulting in the abnormalities. There was no lymph node metastasis or distant metastasis, and he was diagnosed with clinical stage IIIB PPC.

He was admitted to the hospital, and tumor resection around the spinal cord and thoracic posterior vertebral fusion were performed. Chemotherapy with cisplatin (CDDP) + S-1 was performed on day 10 of hospitalization, and concurrent radiotherapy was started from day 16. Two courses of chemotherapy with CDDP + S-1 and radiotherapy of 66 Gy were completed. Durvalumab treatment as consolidation therapy was started nine weeks after the first chemotherapy day. At the start of durvalumab treatment, the tumor size was 61 × 47 mm (Fig 3), which was approximately 22% smaller than the size at diagnosis. Radiation pneumonitis occurred 14 weeks after the start of radiotherapy, but the shadow was slight and asymptomatic, and durvalumab treatment was continued. One year of continuous durvalumab treatment was completed, and he did not show apparent signs of relapse or severe adverse events. The tumor size was 46 × 39 mm at the end of durvalumab treatment (Fig 4).

Discussion

According to the 2015 World Health Organization classification,1 PPC is defined as a poorly differentiated NSCLC, namely a squamous cell carcinoma, adenocarcinoma, or undifferentiated NSCLC with at least 10% spindle and/or giant cells or a carcinoma with only spindle and giant cells.

Bae et al.13 reported cytotoxic chemotherapy was administered for postoperative relapse and inoperable cases and 11 of 13 cases involved progressive disease, with a median overall survival (OS) of approximately five months.2 Similarly, some PPC cases treated with cytotoxic chemotherapy have been reported,3,4 but the median OS was only 7–8 months. Some reports have mentioned that a regimen involving gemcitabine2–7 or taxanes8,9 is effective. Tamura et al. reported chemoradiotherapy for postoperative relapse and locally advanced cases, in which one of the three cases had a long-term response, with progression-free survival of over 65 months.4 Similar cases have been reported,5 and combination radiotherapy and cytotoxic chemotherapy might achieve a long-term response.

Recently, ICIs have been approved for the treatment of NSCLC. PD-L1 expression is recognized as a predictor of the ICI effect,10 and the TPS of PD-L1 of ≥50% in NSCLC has been reported to be 23.2%.11 Conversely, in PPC, the TPS of PD-L1 of ≥50% has been reported to be 60% and that of ≥1% has been reported to be 91.4%.12 Based on

Figure 1 (a) The chest radiography revealed a mass shadow in the right upper lung. (b, c) The chest high resolution computed tomography (CT) scan showed a tumor in the right upper lobe. The tumor size was 70 × 69 mm with a necrotic center.
Figure 2 (a) Histopathology showed a pleomorphic carcinoma with spindle and giant cells. Hematoxylin and eosin staining, ×100 magnification and (b) ×400 magnification. (c) The PD-L1 expression was 100% (×400 magnification).

Figure 3 (a, b) At the start of durvalumab treatment, the tumor size was 61 mm × 47 mm, which was approximately 22% smaller than that at diagnosis.

Figure 4 (a, b) At the end of durvalumab treatment, the tumor size was 46 mm × 39 mm, which was approximately 39% smaller than that at diagnosis.
these findings, PD-L1 expression is believed to be higher in PPC than in NSCLC. It has been reported that PD-L1 is frequently expressed around sarcoma components and necrotic tissues in PPC and that high PD-L1 expression is associated with a poor prognosis.\textsuperscript{13,14} Some reports have mentioned that treatment with ICIs is effective in PPC with high PD-L1 expression.\textsuperscript{15,16} However, in some patients, only a short-term response has been obtained, although PD-L1 expression was \textgtr 95%.\textsuperscript{15} Thus, a high PD-L1 expression is not necessarily a predictor of the ICI effect. According to a study by Kanazu et al. tumor mutation burden might be a predictor of the ICI effect, but this has not yet been applied in clinical practice.\textsuperscript{15}

Durvalumab treatment has been approved as a consolidation therapy after chemoradiotherapy for inoperable stage III NSCLC. In many cases, radiation pneumonia develops during durvalumab treatment. In the PACIFIC study, 18.7% of cases in the durvalumab group developed grade 1–2 radiation pneumonia.\textsuperscript{17} However, in the present case, the patient was asymptomatic and was able to continue durvalumab treatment.

In conclusion, this patient may be cured with chemoradiotherapy. However, the combination of the abscopal effect and ICIs has been previously reported,\textsuperscript{18,19} and may have a better effect than radiotherapy alone. This case suggests a synergic effect of the combination therapy, and further accumulation of cases and formal clinical trials are expected.

**Acknowledgments**

The authors would like to thank Enago (www.enago.jp) for the English language review.

**Disclosure**

The authors state that they have no conflict of interests.

**References**

1. Travis WD, Brambilla E, Nicholson AG et al. The 2015 World Health Organization classification of lung tumors: Impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 2015; 10: 1243–60.
2. Bae HM, Min HS, Lee SH et al. Palliative chemotherapy for pulmonary pleomorphic carcinoma. Lung Cancer 2007; 58: 112–5.
3. Hong JY, Choi MK, Uhm JE et al. The role of palliative chemotherapy for advanced pulmonary pleomorphic carcinoma. Med Oncol 2009; 26: 287–91.
4. Tamura Y, Fujiwara Y, Yamamoto N et al. Retrospective analysis of the efficacy of chemotherapy and molecular targeted therapy for advanced pulmonary pleomorphic carcinoma. BMC Res Notes 2015; 8: 800.
5. Kaira K, Horie Y, Ayabe E et al. Pulmonary pleomorphic carcinoma: A Clinicopathological study including EGFR mutation analysis. J Thorac Oncol 2010; 5: 460–5.
6. Tamiya A, Asami K, Shimizu S et al. Long-term complete response in a patient with disseminated pulmonary pleomorphic carcinoma induced by Cisplatin and gemcitabine. Intern Med 2014; 53: 2625–8.
7. Yamanashi K, Marumo S, Miura K et al. Long-term survival in a case of pleomorphic carcinoma with a brain metastasis. Case Rep Oncol 2014; 7: 799–803.
8. Kato D, Chihara Y, Shirase T, Takahashi T, Takahashi KI, Sakai N. Successful treatment of two consecutive cases of pulmonary pleomorphic carcinoma with platinum chemotherapy. Oncol Lett 2015; 10: 3040–2.
9. Yamamoto M, Manabe S, Moriyama Y et al. Long-term remission achieved via combined chemotherapy and radiotherapy in a non-resectable granulocyte Colony-stimulating factor producing pleomorphic carcinoma of the lung. Intern Med 2013; 52: 2259–63.
10. Shukuya T, Carbone DP. Predictive markers for the efficacy of anti-PD-1/PD-L1 antibodies in lung cancer. J Thorac Oncol 2016; 11: 976–88.
11. Garon EB, Rizvi NA, Hui R et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372: 2018–28.
12. Naito M, Tamiya A, Takeda M et al. A high PD-L1 expression in pulmonary pleomorphic carcinoma correlates with parietal-pleural invasion and might predict a poor prognosis. Intern Med 2019; 58: 921–7.
13. Kim S, Kim MY, Koh J et al. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas. Eur J Cancer 2015; 51: 2698–707.
14. Chang YL, Yang CY, Lin MW et al. High co-expression of PD-L1 and HIF-1α correlates with tumour necrosis in pulmonary pleomorphic carcinoma. Eur J Cancer 2016; 60: 125–35.
15. Kanazu M, Uenami T, Yano Y et al. Case series of pleomorphic carcinomas of the lung treated with nivolumab. Thorac Cancer 2017; 8: 724–8.
16. Fujimoto E, Yokoi T, Mikami K et al. Successful treatment of pulmonary pleomorphic carcinoma with Nivolumab: A case report. Case Rep Oncol 2018; 11: 336–40.
17. Antonia SJ, Villegas A, Daniel D et al. Overall survival with Durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 2018; 379: 2342–50.
18. Liu Y, Dong Y, Kong L et al. Abscopal effect of radiotherapy combined with immune checkpoint inhibitors. J Hematol Oncol 2018; 11: 104.
19. Garelli E, Rittmeyer A, Putora PM et al. Abscopal effect in lung cancer: Three case reports and a concise review. Immunotherapy 2019; 11: 1445–61.